Leap Therapeutics Jumps 170% After $50M Zcash Purchase Backed by Winklevoss
Leap Therapeutics surged roughly 170% on Nov. 12 after revealing a strategic shift from biotech toward a crypto-focused business model and a $50 million buy of Zcash's native token, ZEC. The announcement, which includes backing from Winklevoss Capital, surprised investors and sent the company's equity sharply higher as markets repriced the firm around its new digital-asset position.
The move highlights growing institutional interest in privacy-focused coins and shows how marquee backers can quickly change market sentiment. It also raises execution and regulatory questions for a company transitioning sectors — from custody and compliance to token liquidity and disclosure — so traders should watch Leap's filings and ZEC market dynamics for signs the pivot is sustainable.